Full history for every metric is available with a Kvantra account
Mural Oncology plc (MURA)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -138 | -106 | |||||
| Net profit | $m | - | - | -175 | -190 | -207 | -129 | -119 |
| EPS reported | $ | -7.58 | -6.93 | |||||
| Operating cashflow per share | $ | -7.58 | -5.00 | |||||
| Capex per share | $ | 0.01 | 0.00 | |||||
| FCF per share | $ | -7.59 | -5.00 | |||||
| Free cash flow | $m | -129 | -118 | |||||
| Net debt | $m | -144 | -59 | |||||
| Book value equity | $m | 141 | 55 | |||||
| Book value per share | $ | 8.29 | 3.19 | |||||
| Number of shares | m | 16.96 | 17.32 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.39 | 0.64 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.42 | -0.30 | |||||
| EV/EBITDA LTM | x | 0.42 | 0.20 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -235.39% | -240.05% | |||||
| FCF Yield | % | -235.62% | -334.77% | |||||
| Quality | ||||||||
| ROE | % | -91.47% | -114.70% | |||||
| ROIC | % | -92.94% | -118.68% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -16.04 | -33.39 | |||||
| Net Debt/EBITDA | x | 0.86 | 0.67 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -264.47% | -166.38% | |||||
| Net debt/Equity | x | -1.03 | -1.07 | |||||
| Gross debt/equity | x | 0.06 | 0.06 | |||||
Company overview
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mural Oncology plc (MURA)
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free